Iambic Therapeutics, Inc. — Form 8-K

Iambic Therapeutics, Inc. (ticker: IAM, Nasdaq) completed its initial public offering on October 16, 2026, and filed an amended and restated certificate of incorporation and bylaws effective upon IPO closing. The company changed its name from entos, Inc. (originally incorporated October 14, 2019) to Iambic Therapeutics, Inc. The restated certificate authorizes 1.1 billion total shares (1 billion common at $0.001 par, 100 million preferred at $0.001 par), implements a three-class staggered board, prohibits cumulative voting, requires 66⅔% supermajority to amend specified governance provisions, and restricts stockholder action to formal meetings (no written consent post-IPO). The bylaws establish advance notice requirements for director nominations (120–90 days prior to annual meeting), classified board election, limited special meeting rights (board/CEO/chair only), and extensive indemnification protections for directors and officers.